Literature DB >> 7527640

FK 506 as an alternative in cyclosporin-induced hemolytic uremic syndrome in a kidney transplant recipient.

A H Abdalla1, M H al-Sulaiman, A A al-Khader.   

Abstract

We describe a patient who received a living related kidney transplant that worked very well initially but developed oliguria and renal failure within 1 week and required dialysis. Clinical and hemological changes, as well as renal biopsy, confirmed the diagnosis of cyclosporin-induced hemolytic uremic syndrome. The patient did not respond to antirejection therapy or plasma exchange but did respond to the withdrawal of cyclosporin A and the commencement of FK 506.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527640     DOI: 10.1007/bf00336717

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  3 in total

Review 1.  Drug-induced thrombotic microangiopathy: incidence, prevention and management.

Authors:  R Pisoni; P Ruggenenti; G Remuzzi
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

2.  Tacrolimus (FK506)-Associated Renal Pathology.

Authors:  Parmjeet S Randhawa; Thomas E Starzl; Anthony Jake Demetris
Journal:  Adv Anat Pathol       Date:  1997-07       Impact factor: 3.875

3.  Achalasia in a Patient Undergoing Hematologic Stem Cell Transplant After Exposure to Tacrolimus.

Authors:  Sencer Goklemez; Lauren M Curtis; Alao Hawwa; Alexander Ling; Daniele Avila; Theo Heller; Steven Z Pavletic
Journal:  Mayo Clin Proc Innov Qual Outcomes       Date:  2017-08-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.